Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Short telomere length is associated with NOTCH1/SF3B1/TP53 aberrations and poor outcome in newly diagnosed chronic lymphocytic leukemia patients

Mansouri, Larry ; Grabowski, Pawel ; Degerman, Sofie ; Svenson, Ulrika ; Gunnarsson, Rebeqa ; Cahill, Nicola ; Smedby, Karin Ekstrom ; Geisler, Christian ; Juliusson, Gunnar LU and Roos, Goran , et al. (2013) In American Journal of Hematology 88(8). p.647-651
Abstract
Most previous studies on telomere length (TL) in chronic lymphocytic leukemia (CLL) are based on referral cohorts including a high proportion of aggressive cases. Here, the impact of TL was analyzed in a population-based cohort of newly diagnosed CLL (n=265) and in relation to other prognostic markers. Short telomeres were particularly associated with high-risk genetic markers, such as NOTCH1, SF3B1, or TP53 aberrations, and predicted a short time to treatment (TTT) and overall survival (OS) (both P<0.0001). TL was an independent prognostic factor and subdivided patients with otherwise good-prognostic features (e.g., mutated IGHV genes, favorable cytogenetics) into subgroups with different outcome. Furthermore, in follow-up samples... (More)
Most previous studies on telomere length (TL) in chronic lymphocytic leukemia (CLL) are based on referral cohorts including a high proportion of aggressive cases. Here, the impact of TL was analyzed in a population-based cohort of newly diagnosed CLL (n=265) and in relation to other prognostic markers. Short telomeres were particularly associated with high-risk genetic markers, such as NOTCH1, SF3B1, or TP53 aberrations, and predicted a short time to treatment (TTT) and overall survival (OS) (both P<0.0001). TL was an independent prognostic factor and subdivided patients with otherwise good-prognostic features (e.g., mutated IGHV genes, favorable cytogenetics) into subgroups with different outcome. Furthermore, in follow-up samples (n=119) taken 5-8 years after diagnosis, TL correlated well with TL at diagnosis and remained unaffected by treatment. Altogether, these novel data indicate that short TL already at diagnosis is associated with poor outcome in CLL and that TL can be measured at later stages of the disease. Am. J. Hematol. 88:647-651, 2013. (c) 2013 Wiley Periodicals, Inc. (Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; and (Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
American Journal of Hematology
volume
88
issue
8
pages
647 - 651
publisher
John Wiley & Sons Inc.
external identifiers
  • wos:000322160900004
  • scopus:84880817281
  • pmid:23620080
ISSN
0361-8609
DOI
10.1002/ajh.23466
language
English
LU publication?
yes
additional info
The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Hematology/Transplantation (013022014)
id
2df4ca16-0123-4550-ad1a-99ec71ee8582 (old id 4033584)
date added to LUP
2016-04-01 10:33:48
date last changed
2022-05-25 04:54:33
@article{2df4ca16-0123-4550-ad1a-99ec71ee8582,
  abstract     = {{Most previous studies on telomere length (TL) in chronic lymphocytic leukemia (CLL) are based on referral cohorts including a high proportion of aggressive cases. Here, the impact of TL was analyzed in a population-based cohort of newly diagnosed CLL (n=265) and in relation to other prognostic markers. Short telomeres were particularly associated with high-risk genetic markers, such as NOTCH1, SF3B1, or TP53 aberrations, and predicted a short time to treatment (TTT) and overall survival (OS) (both P&lt;0.0001). TL was an independent prognostic factor and subdivided patients with otherwise good-prognostic features (e.g., mutated IGHV genes, favorable cytogenetics) into subgroups with different outcome. Furthermore, in follow-up samples (n=119) taken 5-8 years after diagnosis, TL correlated well with TL at diagnosis and remained unaffected by treatment. Altogether, these novel data indicate that short TL already at diagnosis is associated with poor outcome in CLL and that TL can be measured at later stages of the disease. Am. J. Hematol. 88:647-651, 2013. (c) 2013 Wiley Periodicals, Inc.}},
  author       = {{Mansouri, Larry and Grabowski, Pawel and Degerman, Sofie and Svenson, Ulrika and Gunnarsson, Rebeqa and Cahill, Nicola and Smedby, Karin Ekstrom and Geisler, Christian and Juliusson, Gunnar and Roos, Goran and Rosenquist, Richard}},
  issn         = {{0361-8609}},
  language     = {{eng}},
  number       = {{8}},
  pages        = {{647--651}},
  publisher    = {{John Wiley & Sons Inc.}},
  series       = {{American Journal of Hematology}},
  title        = {{Short telomere length is associated with NOTCH1/SF3B1/TP53 aberrations and poor outcome in newly diagnosed chronic lymphocytic leukemia patients}},
  url          = {{http://dx.doi.org/10.1002/ajh.23466}},
  doi          = {{10.1002/ajh.23466}},
  volume       = {{88}},
  year         = {{2013}},
}